Cardiothoracic & vascular anesthesia
Cost-Effectiveness of Cryopreserved vs Liquid-Stored Platelets for Managing Surgical Bleeding
Primary result · Per-patient costResult — go to the resultMean difference 15 035 A$ 95% CI -A$1878 to A$31 949Authors' conclusion
In this economic evaluation, cryopreserved platelets were dominated by liquid-stored platelets for managing bleeding in cardiac surgery.
Study context
- Population
- Adults undergoing cardiac surgery at high risk for platelet transfusion, 11 Australian tertiary hospitals, August 2021–April 2024
- Participants
- 202 adults
- Comparison
- Cryopreserved vs liquid-stored platelets
- Cryopreservedn = 104
- Liquid-storedn = 98reference
- Primary endpoint
- Per-patient cost (2023 A$; Intensive care unit (ICU) admissions, hospitalisations, blood products)
- Follow-up
- 90 days
Methodological detailscost-effectiveness analysis, Australian government funder perspective, multicentre
- Cost-effectiveness analysis
- Australian government funder perspective
- Multicentre
Primary result
Per-patient cost
Mean difference
15 035 A$
95% CI -A$1878 to A$31 949
As reported in the abstract
Further findings
| Outcome | Estimate | |
|---|---|---|
| Blood loss within 24 h after ICU admission | mean difference 121 mL (95% CI 5–237) | |
| Total postoperative blood loss | difference 504 mL (95% CI 145–862) | |
| −50005001000Difference, mL (linear scale) |
| Outcome | Difference (95% CI) | |
|---|---|---|
| Type 4 bleeding (BARC criteria) | 12.3% (1%–23.6%) | |
| 90-day mortality | 7.4% (−0.3% to 15.1%) | |
| −100102030Difference (linear scale) |
Safety
Events
| Outcome | Cryopreserved | Liquid-stored |
|---|---|---|
| Serious adverse events | 1 | 1 |
Original publication
Cost-Effectiveness of Cryopreserved vs Liquid-Stored Platelets for Managing Surgical Bleeding. JAMA Netw Open. Published 1 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →